Biotech

The Medicines Company Discontinues Phase 2b Trial of MDCO-2010

PARSIPPANY, NJ: ...

Medifocus Inc. to Attend Two Upcoming Regional American Urological Association (AUA) Meetings to Promote the Prolieve(R) Device System

COLUMBIA, MD and TORONTO: ...

Zenmark Names REVESTIVE (teduglutide): A New Drug for the Treatment of Short Bowel Syndrome

SAN FRANCISCO, CA: ...

Boston Therapeutics Wins FDA Approval to File an Abbreviated New Drug Application for PAZAMET(TM) to Treat Diabetes

MANCHESTER, NH: ...

Prima BioMed Releases Quarterly Shareholder Newsletter, Update on "CANVAS" Study Progress

SYDNEY, AUSTRALIA: ...

Theratechnologies to Announce Financial Results for Third Quarter of 2012

MONTREAL, QUEBEC: ...

Lpath Begins iSONEP Dosing in Nexus Phase 2 Study

SAN DIEGO, CA: Nexus Trial to Study Effects of Anti-S1P Monoclonal Antibody in Wet-AMD Patients ...

Charles Hensley, Ph.D., and Itonis Pharmaceuticals Announce Anti-HIV Compound Targeting the Viral Entry Step

IRVINE, CA: ...

Sarepta Therapeutics Announces Eteplirsen Meets Primary Endpoint of Increased Novel Dystrophin and Achieves Significant Clinical Benefit on 6-Minute Walk Test After 48 Weeks of Treatment in Phase IIb Study in Duchenne Muscular Dystrophy

CAMBRIDGE, MA: Eteplirsen Results in an Increase in Novel Dystrophin to 47% of Normal After 48 Weeks of Treatment; Eteplirsen 50mg/kg Weekly Demonstrates Continued Clinical Benefit of 89.4 Meters in 6-Minute Walk Te ...

Ceapro Announces Termination of Investor Relations Contract

EDMONTON, ALBERTA, CANADA: ...